Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus

Exclusion Criteria

• •1. Participants who have a history of taking once-weekly dosing of DPP-4 inhibitor (trelagliptin or omarigliptin).
• •2. Participants who are being treated with drugs other than those for once-daily oral dosing for the purpose of treatment of chronic complication (for example, "BENET® Tablets 75 mg", a therapeutic agent for osteoporosis which is administered once monthly).
• •3. Participants who are being treated with twice-daily dosing of DPP-4 inhibitor (vildagliptin or anagliptin).
• •4. Participants who are being treated with anti-diabetic fixed-dose combination pill contained a DPP-4 inhibitor.
• •5. Participants with moderate or severe renal impairment (for example, participant whose estimated glomerular filtration rate (eGFR) is below 60 mL/min/1.73m\^2).
• •6. Participants for whom blood sugar control by insulin preparations is desired (for example, participants with severe ketosis, diabetic coma or precoma, type 1 diabetes mellitus, severe infection, or serious trauma before or after surgery).
• •7. Participants who have a history of hypersensitivity or allergy to DPP-4 inhibitor.
• •8. Participants with serious heart disease, cerebrovascular disorder, or participants with serious disease in the pancreas, blood, etc.
• •9. Participants with unstable proliferative diabetic retinopathy.
• •10. Participants with malignant tumor.
• •11. Participants who are pregnant, breast-feeding, possibly pregnant, or planning to become pregnant.
• •12. Participants participating in other clinical studies.
• •13. Participants who have been determined as inappropriate participants by the investigator.